Community-associated methicillin-resistant Staphylococcus aureus: Reconsideration of therapeutic options

Current Infectious Disease Reports

Volumn 8, Issue 1, 2006, Pages 23-30

  Levison, Matthew E ^a   Fung, Shirley ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINOGLYCOSIDE DERIVATIVE; ANTIINFECTIVE AGENT; BETA LACTAM DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOPAMINE; GATIFLOXACIN; GEMIFLOXACIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINEZOLID; METHYLPREDNISOLONE; MINOCYCLINE; MOXIFLOXACIN; PENICILLIN BINDING PROTEIN 2A; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; PSEUDOMONIC ACID; QUINOLONE DERIVATIVE; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; TELITHROMYCIN; TIGECYCLINE; VANCOMYCIN; WARFARIN;

ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; BACTEREMIA; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL TRIAL; COLITIS; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTACT DERMATITIS; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SUBSTITUTION; ENDOCARDITIS; ENVIRONMENTAL EXPOSURE; EPIDEMIC; ESOPHAGITIS; FOOD DRUG INTERACTION; GENE CASSETTE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; INSTITUTIONAL CARE; INTRAVENOUS DRUG ABUSE; LIVER TOXICITY; LOW DRUG DOSE; MENTAL DEFICIENCY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; MYOPATHY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIC NERVE DISEASE; PENICILLIN RESISTANCE; PERIPHERAL NEUROPATHY; PHLEBITIS; PREGNANCY; PROTHROMBIN TIME; PRURITUS; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SEROTONIN SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SKIN BURNING SENSATION; SPUTUM DISCOLORATION; STAPHYLOCOCCUS INFECTION; SWEAT DISCOLORATION; THROMBOCYTOPENIA; TOOTH DISCOLORATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; VEIN CATHETERIZATION;

EID: 31544472583     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0031-7     Document Type: Review

References (68)

1. Narita S, Kaneko J, Chiba J, et al.: Phage conversion of Panton-Valentine leucocidin in Staphylococcus aureus: molecular analysis of a PVL-converting phage, phiSLT. Gene 2001, 268:195-206.
2. Vandenesch F, Naimi T, Enright MC, et al.: Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leucocidin genes: worldwide emergence. Emerg Infect Dis 2003, 9:978-984.
3. Robinson DA, Kearns AM, Holmes A, et al.: Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 2005, 365:1256-1258.
4. Katayama Y, Ito T, Hiramatsu K: A new class of genetic element, Staphylococcal cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000, 44:1549-1555.
5. Robinson DA, Enright MC: Multilocus sequence typing and the evolution of methicillin-resistant Staphylococcus aureus. Clin Micobiol Infect 2004, 10:92-97.
6. Daum RS, Ito T, Hiramatsu K, et al.: A novel methicillin resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002, 186:1344-1347.
7. Baba T, Takeuchi F, Kuroda M, et al.: Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002, 359:1819-1827.
8. Panton PN, Valentine FCO: Staphylococcal toxin. Lancet 1932, 222:506-508.
9. Ward PD, Turner WH: Identification of staphylococcal Panton-Valentine leucocidin as a potent dermonecrotic toxin. Infect Immun 1980, 28:393-397.
10. Gillet Y, Issartel B, Vanhems P, et al.: Association between Staphylococcus aureus strains carrying Panton-Valentine leucocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 2002, 359:753-759.
11. Gauduchon V, Cozon G, Vandenesch F, et al.: Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004, 189:346-353.
12. Cribier B, Prevost G, Couppie P, et al.: Staphylococcus aureus leucocidin: a new virulence factor in cutaneous infections? An epidemiological and experimental study. Dermatology 1992, 185:175-180.
13. Lina G, Piemont Y, Godail-Gamot F, et al.: Involvement of Panton-Valentine leucocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29:1128-1132.
14. Saravolatz LD, Markowitz N, Arking L, et al.: Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-wide outbreak. Ann Intern Med 1982, 96:11-16.
15. Kazakova SV, Hageman JC, Matava M, et al.: A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005, 352:468-475.
16. Centers for Disease Control and Prevention: Methicillin-resistant Staphylococcus aureus infections in correctional facilities - Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 2003, 52:992-996.
17. Groom AV, Wolsey DH, Naimi TS, et al.: Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001, 286:1201-1205.
18. Charlebois ED, Bangsberg DR, Moss NJ, et al.: Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis 2002, 34:425-433.
19. Lindenmeyer JM, Schoenfeld S, O'Grady R, Carney JK: Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community. Arch Intern Med 1998, 158:895-899.
20. Lee NE, Taylor MM, Bancroft E, et al.: Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 2005, 40:1529-1534.
21. Centers for Disease Control and Prevention: Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. MMWR 1999, 48:707-710.
22. Herold BC, Immergluck LC, Maranan MC, et al.: Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998, 279:593-598.
23. Frazee BW, Lynn J, Charlebois ED, et al.: High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005, 45:311-20.
24. Chambers HF: The changing epidemiology of Staphylococcus aureus. Emerg Infect Dis 2001, 7:178-181.
25. O'Brien FG, Pearman JW, Gracey M, et al.: Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol 1999, 37:2858-2862.
26. Carleton J, Charlebois ED, Pedreau-Remington F: Dramatic increase of staphylococcal chromosomal cassette mec (SCC mec) type IV in both a nosocomial and community setting. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology; 2003.
27. Salgado CD, Farr BM, Calfee DF: Community-acquired methicillin-resistant Staphylococcus aureus: a metaanalysis of prevalence and risk factors. Clin Infect Dis 2003, 36:131-136.
28. Johnson LB, Bhan A, Pawlak J, et al.: Changing epidemiology of community-acquired methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2003, 24:431-435.
29. Jernigan J, Pullen AL, Partin C, Jarvis WR: Prevalence of and risk factors for colonization with methicillin-resistant Staphylococcus aureus in an outpatient clinic population. Infect Control Hosp Epidemiol 2003, 24:445-450.
30. Fung S, Levison ME: Low incidence of community-acquired MRSA infections in a Philadelphia acute care teaching hospital. Paper presented at the Infectious Diseases Society of America 42nd Annual Meeting. Boston, MA; September 30-October3, 2004.
31. Charlebois ED, Perdreau-Remington F, Kreisworth B, et al.: Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004, 39:47-54.
32. Fridkin SK, Hageman JC, Morrison M, et al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352:1436-1444.
33. Naimi TS, LeDell KH, Boxrud DM, et al.: Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001, 33:990-996.
34. Levine D, Fromm BS, Reddy BR: Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991, 115:674-680.
35. Carpenter CF, Chambers HF: Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004, 38:994-1000.
36. Silverman JA, Mortin LI, Vanpraagh AD, et al.: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005, 191:2149-2152.
37. Frank AL, Marcinak JF, Mangat PD, et al.: Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis 2002, 21:530-534.
38. Martinez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL: Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003, 22:593-598.
39. Siberry GK, Tekle T, Carroll K, Dick J: Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003, 37:1257-1260.
40. Eliopoulos GM: Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003, 36:473-481.
41. Lina G, Quaglia A, Reverdy ME, Leclercq R, et al.: Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999, 43:1062-1066.
42. Fuchs PC, Barr AL, Brown SD: Bactericidal activity of quinupristin /dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator. Antimicrob Agents Chemother 2000, 44:2880-2882.
43. Fantin B, Leclerq R, Merlé Y, et al.: Critical influence of resistance to streptogramin B type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due Staphylococcus aureus. Antimicrob Agents Chemother 1995, 39:400-405.
44. Zarrouk V, Bozdogan B, Leclercq R, et al.: Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother 2000, 44:1168-1173.
45. Vouillamoz J, Entenza JM, Feger C, et al.: Quinupristin-dalfopristin combined with β-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolides-lincosamides-streptogramin B Antibiotics. Antimicrob Agents Chemother 2000, 44:1789-1795.
46. Pavie P, Lefort A, Zarrouk V, et al.: Efficacies of Quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics. Antimicrob Agents Chemother 2002, 46:3061-3064.
47. Fantin B, Leclercq R, Ottaviani M, et al.: In vivo activities and penetration of RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother 1994, 38:432-437.
48. Zarrouk V, Bozdogan B, Leclercq R, et al.: Activities of the combination of quinupristin-dalfopristin and rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics. Antimicrob Agents Chemother 2001, 45:1244-1248.
49. Stevens DL, Herr D, Lampiris H, et al.: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002, 34:1481-1490.
50. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ: Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surgical Infect 2003, 4:57-70.
51. Kollef MH, Rello J, Cammarata SK, et al.: Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blinded studies comparing linezolid with vancomycin. Intensive Care Med 2004, 30:343-346.
52. Bressler AM, Zimmer SM, Gilmore JL, Somani J: Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004, 4:528-531.
53. Lee E, Burger S, Shah J, et al.: Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003, 37:1389-1391.
54. Frippiat F, Bergiers C, Michel C, et al.: Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 2004, 53:1114-1115.
55. Gillman PK: Linezolid and serotonin toxicity. Clin Infect Dis 2003, 37:1274-1275.
56. Bernard L, Stern R, Lew D, Hoffmeyer P: Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 2003, 36:1197.
57. Boucher HW, Wennerstein CB, Eliopoulos GM: In vitro activity of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000, 44:2225-2229.
58. Markowitz N, Quinn EL, Saravolatz LD: Trimethoprim/ Sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infections. Ann Intern Med 1992, 117:390-398.
59. Mandell GL: Interaction of intraleukocytic bacteria and antibiotics. J Clin Invest 1973, 52:1673-1679.
60. Zimmerli W, Widmer AF, Blatter M, et al.: Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-body infection (FBI) study group. JAMA 1998, 279:1537-1541.
61. Norden CW, Bryant R, Palmer D, et al.: Chronic osteomyell tis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986, 79:947-951.
62. Schmitz FJ, Fluit AC, Hafner D, et al.: Development of resistance to ciprofloxacin, rifampin and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2000, 44:3229-3231.
63. Shopsin B, Zhao X, Kreiswirth BN, et al.: Are the new quinolone appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int J Antimicrob Agents 2004, 24:32-34.
64. Firsov AA, Vostrov SN, Lubenko IY, et al.: In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47:1604-1613.
65. Firsov AA, Vostrov SN, Lubenko IY, et al.: Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. J Antimicrob Agents 2004, 23:451-456.
66. Postier RG, Green SL, Klein SR, et al.: Results of a multi-center, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Therapeutics 2004, 26:704-714.
67. Miller LG, Perdreau-Remington F, Rieg G, et al.: Necrotizing fasciitis caused by Community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005, 352:1445-1453.
68. Hidron AI, Kourbatova EV, Halvosa JS, et al.: Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: Emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005, 41:159-166.